Search

Your search keyword '"Ghesquières, Hervé"' showing total 626 results

Search Constraints

Start Over You searched for: Author "Ghesquières, Hervé" Remove constraint Author: "Ghesquières, Hervé"
626 results on '"Ghesquières, Hervé"'

Search Results

1. High-dose chemotherapy with autologous haematopoietic stem cell transplantation in patients with isolated vitreoretinal lymphoma: a LOC network study

2. Distinct Hodgkin lymphoma subtypes defined by noninvasive genomic profiling

3. Classic Hodgkin Lymphoma: The LYSA pragmatic guidelines

4. Autologous stem cell transplantation in T-cell/histiocyte-rich large B-cell lymphoma: EBMT Lymphoma Working Party study

5. Health-related quality of life profile of newly diagnosed patients with Hodgkin and non-Hodgkin lymphomas: A real-world study including 3922 patients from the French REALYSA cohort

6. A quick access to information on influenza burden and prevention in Lyon university hospital: A prospective QR code-based information campaign in 2022–2023

7. The phase 2 LYSA study of prednisone, vinblastine, doxorubicin, and bendamustine for untreated Hodgkin lymphoma in older patients

8. Challenges for quality and utilization of real-world data for diffuse large B-cell lymphoma in REALYSA, a LYSA cohort

9. Brentuximab vedotin with AVD for stage II–IV HIV-related Hodgkin lymphoma (AMC 085): phase 2 results from an open-label, single arm, multicentre phase 1/2 trial

10. Distinct germline genetic susceptibility profiles identified for common non-Hodgkin lymphoma subtypes

11. HLA-DR expression on monocytes and outcome of anti-CD19 CAR T-cell therapy for large B-cell lymphoma

12. BTG1 inactivation drives lymphomagenesis and promotes lymphoma dissemination through activation of BCAR1

13. Correction: Distinct germline genetic susceptibility profiles identified for common non-Hodgkin lymphoma subtypes

14. Genetic overlap between autoimmune diseases and non‐Hodgkin lymphoma subtypes

15. Outcomes of older patients with diffuse large B-cell lymphoma treated with R-CHOP: 10-year follow-up of the LNH03-6B trial

17. Intensive chemotherapy followed by autologous stem cell transplantation in primary central nervous system lymphomas (PCNSLs). Therapeutic outcomes in real life—experience of the French Network

18. End-of-life management of multiple myeloma patients in the era of CD38 and immunotherapy.

19. Hodgkin Lymphoma, Classical

21. Clinicopathological features and survival in EBV-positive diffuse large B-cell lymphoma not otherwise specified

22. Incidence of central nervous system relapses in patients with DLBCL treated with lenalidomide as maintenance after R-CHOP

23. IELSG38: phase II trial of front-line chlorambucil plus subcutaneous rituximab induction and maintenance in mucosa-associated lymphoid tissue lymphoma

24. Genetically predicted longer telomere length is associated with increased risk of B-cell lymphoma subtypes

25. Impact on Outcome of Minimal Residual Disease after Hematopoietic Stem Cell Transplantation with Fludarabine, Amsacrine, and Cytosine Arabinoside-Busulfan Conditioning: A Retrospective Monocentric Study

26. A French multicentric prospective prognostic cohort with epidemiological, clinical, biological and treatment information to improve knowledge on lymphoma patients: study protocol of the “REal world dAta in LYmphoma and survival in adults” (REALYSA) cohort

27. Plasticity of Mature B Cells Between Follicular and Classic Hodgkin Lymphomas: A Series of 22 Cases Expanding the Spectrum of Transdifferentiation

28. Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphoma

29. Genome-wide Association Study Identifies Five Susceptibility Loci for Follicular Lymphoma outside the HLA Region

30. Distinct Hodgkin lymphoma subtypes defined by noninvasive genomic profiling

31. Retrospective multicenter comparative study of the efficacy and safety between R-DHAC and R-DHAOx in diffuse large B-cell lymphoma or transformed follicular or marginal zone B lymphoma into aggressive lymphoma, as a second-line treatment

32. ANTIFON-CLIC®, a new clinical decision support system for the treatment of invasive aspergillosis: is it clinically relevant?

34. ABCL-422 Subcutaneous Epcoritamab in Patients With Relapsed or Refractory Large B-Cell Lymphoma (EPCORE NHL-1): Pivotal Results from a Phase 2 Study

36. Brentuximab vedotin with AVD for stage II–IV HIV-related Hodgkin lymphoma (AMC 085): phase 2 results from an open-label, single arm, multicentre phase 1/2 trial

37. Long-lasting CRs after ibrutinib monotherapy for relapse or refractory primary CNS lymphoma (PCNSL) and primary vitreoretinal lymphoma (PVRL): Long-term results of the iLOC study by the Lymphoma Study Association (LYSA) and the French Oculo-Cerebral Lymphoma (LOC) Network (clinical trial number: NCT02542514)

38. Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma

40. Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm, phase 2 trial from the LYSA group

41. Retrospective multicenter comparative study of the efficacy and safety between R-DHAC and R-DHAOx in diffuse large B-cell lymphoma or transformed follicular or marginal zone B lymphoma into aggressive lymphoma, as a second-line treatment.

42. Normal B cells express ZAP70 in chronic lymphocytic leukemia: A link between autoimmunity and lymphoproliferation?

45. Management and outcome of primary CNS lymphoma in the modern era: An LOC network study

46. Brentuximab-vedotin in combination with cyclophosphamide, doxorubicin, prednisolone for the treatment of aggressive CD30-positive cutaneous T-cell lymphomas

47. Correction: Distinct germline genetic susceptibility profiles identified for common non-Hodgkin lymphoma subtypes

48. Correction: Distinct germline genetic susceptibility profiles identified for common non-Hodgkin lymphoma subtypes

49. Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial

50. Gray-zone Lymphoma Between cHL and Large B-Cell Lymphoma: A Histopathologic Series From the LYSA

Catalog

Books, media, physical & digital resources